| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci |
ChiCTR2000030877: Efficacy and safety of toripalimab combined with first-line chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma |
|
|
| Recruiting | 4 | 30 | China | toripalimab combined with first-line chemotherapy | Huashan hospital , Fudan university ; Huashan hospital, Fudan university, scientific research project supported by enterprise | gastric cancer | | | | |
ChiCTR2000029068: Study on Toripalimab combined with chemoradiotherapy for recrrunt or metastatic cervical cancer |
|
|
| Recruiting | 4 | 58 | China | toripalimab combined with chemoradiotherapy | The First Affiliated Hospital of Soochow University ; The First Affiliated Hospital of Soochow University, Self-raised | cervical cancer | | | | |
ChiCTR2000033603: Toripalimab combined with Cetuximab and FOLFIRI for first-line treatment of metastatic unresectable left side, KRAS/NRAS/BRAF wild-type advanced colorectal cancer: a single-arm, open, multicenter clinical study |
|
|
| Recruiting | 4 | 61 | China | Toripalimab combined with Cetuximab and FOLFIRI | Jiangsu Cancer Hospital ; Jiangsu Cancer Hospital, self-financing | Colorectal cancer | | | | |
ChiCTR2000037024: Neoadjuvant therapy of Toripalimab plus Axitinib for Von Hipple-Lindau disease associated clear cell renal cell carcinoma: a single-arm, single-center, prospective study |
|
|
| Recruiting | 4 | 20 | China | Neoadjuvant therapy of Toripalimab plus Axitinib follow by nephrone-sparing surgery | Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine ; Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Self-financing | Von Hippel–Lindau disease | | | | |
ChiCTR2100051293: Intervention study on preoperative application of PD-1 monoclonal antibody combined with gemcitabine and paclitaxel (albumin binding type) in the treatment of borderline resectable and locally advanced pancreatic cancer |
|
|
| Recruiting | 4 | 30 | China | gemcitabine + Albumin paclitaxel + Toripalimab monoclonal antibody | West China Hospital of Sichuan University ; West China Hospital of Sichuan University, Latitudinal project | pancreatic cancer | | | | |
ChiCTR2000038249: Application of Toripalimab combined with TKI in preoperative treatment of patients with advanced renal carcinoma |
|
|
| Recruiting | 4 | 25 | China | Toripalimab combined with TKI | SIR RUN RUN SHAW Hospital affiliated to Zhejiang University School of Medicine ; SIR RUN RUN SHAW Hospital affiliated to Zhejiang University School of Medicine, Shanghai Junshi Biomedical Technology Co., LTD | Renal cell carcinoma | | | | |
ChiCTR2200060671: GEMOX 'chemo holiday' combined with regorafenib and toripalimab for biliary tract cancers with high-risk recurrence after surgery: a multicenter prospective cohort study |
|
|
| Not yet recruiting | 4 | 120 | China | ① GEMOX: a total of 6 courses of treatment. 1 course of treatment was suspended after every 2 courses of treatment. ② Regorafenib: a total of 8 courses of treatment. ③ Toripalimab: a total of 8 courses of treatment. ④ Capecitabine: a total of 8 courses of treatment. ;① GEMOX: a total of 6 courses of treatment. ② Regorafenib: a total of 8 courses of treatment. ③ Toripalimab: a total of 8 courses of treatment. ④ Capecitabine: a total of 8 courses of treatment. ;① GEMOX: a total of 6 courses of treatment. ② Capecitabine: a total of 8 courses of treatment. | Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine ; Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, This work was supported by Scientific Research Fund of Zhejiang Provincial Education Department (Y202148325), and National Natural Science Foundation of China (81800540, 81827804, and 81802330). | Biliary tract cancers | | | | |
ChiCTR2100050060: Clinical study on the safety and efficacy of donafenib tosylate combined with toripalimab injection in first-line/second-line treatment of patients with advanced biliary tract cancer who refuse chemotherapy |
|
|
| Not yet recruiting | 4 | 36 | China | Donafenib tablet, 200 mg BID Po; Toripalimab, 240 mg Q3W IV ;Donafenib tablet, 200 mg BID Po; Toripalimab, 240 mg Q3W IV | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences ; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, self-raised | Biliary tract cancer | | | | |
ChiCTR2100045556: A multicenter, open-label, randomized controlled clinical trail of PD-1 inhibitor (Toripalimab) combined with TPF chemotherapy for neoadjuvant treatment of locally advanced head and neck squamous cell carcinoma |
|
|
| Recruiting | 4 | 100 | China | Toripalimab +Docetaxel + Cisplatin + Fluorouracil ;Docetaxel + Cisplatin + Fluorouracil | Sichuan Cancer Hospital ; Sichuan Cancer Hospital, TopAlliance Biosciences Inc. | Locally advanced head and neck squamous cell carcinoma | | | | |
| Recruiting | 4 | 50 | China | Toripalimab (240mg, q3w) plus Carboplatin-based chemotherapy | Department of Thoracic Surgery, Shanghai Pulmonary Hospital of Tongji University ; Shanghai Pulmonary Hospital of Tongji University, Clinical Research Program of Shanghai Pulmonary Hospital in 2019 | non-small cell lung cancer | | | | |
TRANSPARENT, NCT06457503: A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer |
|
|
| Not yet recruiting | 4 | 100 | NA | Toripalimab, JS001, TAB-001, CHS-007, Cisplatin, Gemcitabine, Carboplatin | Coherus Biosciences, Inc. | Nasopharyngeal Cancer Recurrent | 12/27 | 12/27 | | |
ChiCTR2100049493: Donafenib and Toripalimab in combination with transarterial chemoembolization and bronchial arterial chemoinfusion Versus Donafenib and Toripalimab in the treatment of hepatocellular carcinoma with pulmonary metastasis: a randomized controlled trial |
|
|
| Not yet recruiting | 4 | 130 | China | TACE、BAI combined with donafinib and triprizumab ;donafinib and triprizumab | Department of Interventional Radiology, Chinese People’s Liberation Army General Hospital ; Department of Interventional Radiology, Chinese People’s Liberation Army General Hospital, self-funded | Hepatocellular carcinoma | | | | |
NCT05291910: Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer |
|
|
| Not yet recruiting | 4 | 70 | RoW | Inetetamab, Toripalimab, Albumin-Bound Paclitaxel | Chinese Academy of Medical Sciences | Breast Cancer | 12/24 | 12/25 | | |
ChiCTR2200057408: Efficacy and safety of triplizumab combined with gemcitabine and cisplatin in the treatment of urothelial cancer |
|
|
| Recruiting | 4 | 40 | China | triplizumab combined with paclitaxel ;triplizumab combined with paclitaxe ;triplizumab combined with paclitaxe ;triplizumab combined with paclitaxe | The Second Hospital of Tianjin Medical University ; The Second Hospital of Tianjin Medical University, tianjinshiqingnianrencaituojugongcheng | Urothelial carcinoma | | | | |
ChiCTR2300073731: An single-arm, single-center, observational study of Surufatinib combined with Toripalimab and GEMOX as first-line treatment for advanced intrahepatic cholangiocarcinoma |
|
|
| Not yet recruiting | 4 | 30 | China | Surufatinib combined with Toripalimab and GEMOX | Yichang Central People's Hospital ; Yichang Central People's Hospital, Investigator self-financing | intrahepatic cholangiocarcinoma | | | | |
2020-004437-20: A clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC) |
|
|
| Ongoing | 3 | 519 | Europe | Toripalimab, LENVIMA, TAB001 and JS001, Solution for infusion, Capsule, hard, LENVIMA | Shanghai Junshi Biosciences Co., Ltd, Shanghai Junshi Biosciences Co., Ltd., Shanghai Junshi Biosciences Co., Ltd | advanced hepatocellular carcinoma (HCC), liver cancer, Diseases [C] - Cancer [C04] | | | | |
JUPITER-02, NCT03581786: The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer |
|
|
| Active, not recruiting | 3 | 289 | RoW | TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy, Placebos | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic NPC | 05/20 | 10/22 | | |
|
|
|
|
| Completed | 3 | 514 | RoW | Toripalimab, JS001, TAB001 | Shanghai Junshi Bioscience Co., Ltd. | Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy | 03/21 | 09/23 | | |
|
|
|
NCT04376866: Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 204 | RoW | Toripalimab, JS001 | Cancer Hospital of Guangxi Medical University | Recurrent Nasopharyngeal Carcinoma | 04/23 | 04/28 | | |
RENOTORCH, NCT04394975: Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer |
|
|
| Active, not recruiting | 3 | 421 | RoW | Biological : Toripalimab Drug: Axitinib, sunitinib | Shanghai Junshi Bioscience Co., Ltd. | Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 | 06/23 | 06/23 | | |
NCT03924050: Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI |
|
|
| Recruiting | 3 | 440 | RoW | TORIPALIMAB INJECTION(JS001 ) | Shanghai Junshi Bioscience Co., Ltd. | Non-small Cell Lung Cancer | 07/23 | 08/24 | | |
NCT05015621: A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma |
|
|
| Recruiting | 3 | 194 | RoW | Surufatinib plus Toripalimab, HMPL-012 plus JS001, 5-fluorouracil, Calcium folinate and Irinotecan, FOLFIRI | Hutchison Medipharma Limited | Advanced Neuroendocrine Carcinoma | 05/25 | 05/25 | | |
NCT04709380: Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT |
|
|
| Recruiting | 3 | 85 | RoW | Radiotherapy plus Toripalimab, Sorafenib | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Radiotherapy, Toripalimab, Sorafenib, Advanced Hepatocellular Carcinoma | 03/24 | 08/24 | | |
HEPATORCH, NCT04723004: Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC |
|
|
| Active, not recruiting | 3 | 326 | RoW | Toripalimab combined with Bevacizumab, Sorafenib | Shanghai Junshi Bioscience Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 10/23 | 12/24 | | |
NCT05056337: Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC |
|
|
| Enrolling by invitation | 3 | 220 | RoW | Lenvatinib 4 MG Oral Capsule [Lenvima], Toripalimab, TACE | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 11/23 | 12/23 | | |
NCT04568304: A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma |
|
|
| Not yet recruiting | 3 | 364 | RoW | Toripalimab Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection / Carboplatin Injection, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Locally Advanced or Metastatic Urothelial Carcinoma | 11/23 | 11/25 | | |
NCT04280822: Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma |
|
|
| Recruiting | 3 | 400 | RoW | Neoadjuvant immunochemotherapy | Henan Cancer Hospital | Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival | 12/23 | 03/28 | | |
NCT06170489: A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) |
|
|
| Recruiting | 3 | 185 | RoW | JS004 in combination with Toripalimab, Bendamustine or gemcitabine | Shanghai Junshi Bioscience Co., Ltd. | Hodgkin Lymphoma | 05/25 | 09/27 | | |
NCT06201065: FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial |
|
|
| Recruiting | 3 | 200 | RoW | Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab, oxaliplatin , fluorouracil, and leucovorin | Sun Yat-sen University | Hepatocellular Carcinoma | 07/25 | 12/26 | | |
NCT03430297: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma |
|
|
| Active, not recruiting | 3 | 256 | RoW | JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W | Shanghai Junshi Bioscience Co., Ltd. | Metastatic Melanoma, Unresectable Melanoma | 12/23 | 06/24 | | |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/23 | 12/24 | | |
NCT04711434: PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients |
|
|
| Recruiting | 3 | 260 | RoW | PD-1 Antibody, Toripalimab | Sun Yat-sen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Fujian Cancer Hospital, Guangdong Provincial People's Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, The Third Affiliated Hospital of Kunming Medical College. | Lynch Syndrome | 12/23 | 12/25 | | |
NCT06228079: Adjuvant vs Surgery Only in Early-stage Recurrent NPC |
|
|
| Not yet recruiting | 3 | 176 | RoW | Immunotherapy,Toripalimab Injection, Chemotherapy,Gemcitabine based regimen | Eye & ENT Hospital of Fudan University, Shanghai Zhongshan Hospital, Shanghai 6th People's Hospital, Changhai Hospital, Fujian Medical University Union Hospital, People's Hospital of Guangxi, Shenzhen Second People's Hospital | Recurrent Nasopharyngeal Carcinoma | 06/28 | 06/28 | | |
NCT06277050: Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 264 | RoW | Maintenance Therapy with Toripalimab and Capecitabine, Maintenance Therapy with Capecitabine | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance Therapy | 02/29 | 02/30 | | |
| Active, not recruiting | 3 | 501 | RoW | 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab, Cisplatin;, Carboplatin;, Pemetrexed;, Paclitaxel;, Docetaxel, 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo ) | Shanghai Junshi Bioscience Co., Ltd. | Stage II-III Non-small Cell Lung Cancer | 03/24 | 10/24 | | |
|
| Active, not recruiting | 3 | 530 | Europe, US, RoW | Toripalimab combined with Lenvatinib, Placebo combined with Lenvatinib | Shanghai Junshi Bioscience Co., Ltd., Shanghai Junshi Biosciences Co., Ltd | Advanced Hepatocellular Carcinoma (HCC) | 05/24 | 09/26 | | |
NCT06235203: Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC |
|
|
| Recruiting | 3 | 154 | RoW | endoscopic surgery, Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy, Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy, Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy | Eye & ENT Hospital of Fudan University, Shanghai Zhongshan Hospital, Shanghai 6th People's Hospital, Changhai Hospital, Fujian Medical University Union Hospital, People's Hospital of Guangxi, Shenzhen Second People's Hospital | Recurrent Nasopharyngeal Carcinoma | 06/27 | 06/27 | | |
neoR-TORCH, NCT06437977: Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients |
|
|
| Not yet recruiting | 3 | 478 | NA | SBRT, Toripalimab, Toripalimab IV 240mg + platinum-based doublet chemotherapy | Shanghai Chest Hospital | Stage II-III Non-small Cell Lung Cancer | 06/27 | 06/29 | | |
SCLC, NCT06441344: Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell |
|
|
| Not yet recruiting | 3 | 136 | NA | Toripalimab plus Anlotinib, Toripalimab | Taizhou Hospital | SCLC, Maintenance Treatment | 05/26 | 05/30 | | |
NCT03907826: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients |
|
|
| Recruiting | 3 | 212 | RoW | PD-1 blocking antibody, JS001, GP, IMRT | Sun Yat-sen University | Recurrent Nasopharyngeal Carcinoma | 12/24 | 12/27 | | |
NCT05340491: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial |
|
|
| Recruiting | 3 | 212 | RoW | Toripalimab, JS001, Chemotherapy, GP, Intensity modulated radiotherapy, IMRT | Sun Yat-sen University | Nasopharyngeal Carcinoma | 12/24 | 12/27 | | |
NCT04778956: Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 218 | RoW | Toripalimab, PD-1 antibody, salvage surgery | Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Zhongshan People's Hospital, Guangdong, China, Tenth Affiliated Hospital, Sun Yat-sen University | Nasopharyngeal Carcinoma, PD-1, Surgery | 03/25 | 03/33 | | |
NCT04365036: A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) |
|
|
| Recruiting | 3 | 207 | RoW | Toripalimab, Pegaspargase, Gemcitabine, Oxaliplatin, Definitive intensity-modulated radiotherapy (IMRT) | Sun Yat-sen University | NK/T Cell Lymphoma Nos | 04/25 | 06/25 | | |
DIAMOND, NCT04907370: PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 540 | RoW | PD-1 blocking antibody, PD-1 Blockade, Gemcitabine, GEM, Cisplatin (80mg/m2), DDP, Cisplatin (100mg/m2), Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd. | Nasopharyngeal Carcinoma | 05/25 | 05/27 | | |
NCT04453813: Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 226 | RoW | Toripalimab plus concurrent chemo-radiotherapy, Concurrent chemo-radiotherapy | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Yuebei People's Hospital, Wuzhou Red Cross Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University | Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment | 07/25 | 07/27 | | |
NCT06026878: GNT Induction Treatment in Locally Advanced NPC |
|
|
| Recruiting | 3 | 228 | RoW | gemcitabine,nimotuzumab, toripalimab, GNT, gemcitabine, cisplatin, GP | Air Force Military Medical University, China | Nasopharyngeal Carcinoma | 09/25 | 09/27 | | |
NCT05669092: A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status |
|
|
| Recruiting | 3 | 174 | RoW | Toripalimab, PD-1inhibitor, CRT, LCRT, SCRT, short-course radiotherapy, XELIRI, Capecitabine and Irinotecan, FOLFRINOX, Irinotecan,Oxaliplatin and 5-FU | Zhejiang Cancer Hospital | Toripalimab, Radiation | 12/25 | 12/25 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 3 | 680 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 03/26 | 07/28 | | |
NCT05869227: Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 166 | RoW | Capecitabine/Placebo combined with toripalimab | XIANG YANQUN, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhujiang Hospital | Nasopharyngeal Carcinoma, Maintenance Therapy | 04/26 | 04/29 | | |
ChiCTR2100051031: A multicenter, prospective, randomized controlled study of radiotherapy combined with teriprizumab versus radiotherapy alone in the treatment of elderly patients with locally advanced nasopharyngeal carcinoma |
|
|
| Recruiting | 3 | 164 | | Teriprolizumab treatment ;Radiotherapy alone | Jiangxi Cancer Hospital; Jiangxi Cancer Hospital, none | Nasopharyngeal carcinoma | | | | |
| Not yet recruiting | 3 | 341 | NA | Toripalimab, Cisplatin/Carboplatin, Pemetrexed (non-squamous cell carcinoma)/ Docetaxel/ Gemcitabine/ Vinorelbine/ Paclitaxel, Toripalimab mimetic (placebo) | Shanghai Pulmonary Hospital, Shanghai, China | Non Small Cell Lung Cancer | 12/26 | 12/27 | | |
RC48-C016, NCT05302284: A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma |
|
|
| Recruiting | 3 | 452 | RoW | RC48-ADC, Disitamab Vedotin, Toripalimab, JS001, Gemcitabine, Cisplatin, Carboplatin | RemeGen Co., Ltd. | Urothelial Carcinoma, HER2-expressing | 12/26 | 04/28 | | |
ChiCTR2200055494: A randomized, controlled, single-blind, multicenter Phase II/III clinical study of PD-1 inhibitors combined with chemoraotherapy in the treatment of stage T1-2N2-3/T3-4N0-3M0 nasopharyngeal carcinoma |
|
|
| Recruiting | 3 | 154 | China | 2 cycles of induction chemotherapy + 3 cycles of synchronous chemotherapy + 7 cycles of tiriplizumab immunotherapy ;2 cycles of induction chemotherapy + 3 cycles of synchronous chemotherapy + 7 cycles of placebo | Sichuan Cancer Hospital ; Sichuan Cancer Hospital, Sichuan Cancer Hospital Clinical Scientist Support Program Project | nasopharyngeal carcinoma | | | | |
NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 3 | 663 | RoW | Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel | Shanghai Junshi Bioscience Co., Ltd. | Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | 05/27 | 05/27 | | |
NCT05342194: Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study |
|
|
| Not yet recruiting | 3 | 480 | RoW | Toripalimab, Tuoyi, Lenvatinib mesylate capsules, LENVIMA, Placebo IV, Toripalimab placebo, Oral placebo, Lenvatinib mesylate capsules placebo, Oxaliplatin for injection, Gemcitabine hydrochloride, Cisplatin | Shanghai Junshi Bioscience Co., Ltd. | Intrahepatic Cholangiocarcinoma | 05/27 | 05/27 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
NCT03992911: Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma |
|
|
| Recruiting | 2/3 | 336 | RoW | Simmtecan, 5-FU and l-LV, FOLFSIM regimen, Toripalimab, JS001, Etoposide, Cisplatin, EP regimen, Etoposide, Carboplatin, EC regimen | Peking University | Neuroendocrine Carcinoma of the Bladder | 06/22 | 06/23 | | |
NCT05809336: Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors |
|
|
| Completed | 2/3 | 172 | RoW | Inosine 0.2g orally 3 times/day, Camrelizumab for injection, Sintilimab injection, Penpulimab injection, Tislelizumab injection, Pembrolizumab injection, Toripalimab, Atezolizumab, chemotherapy/targeting, PD-1/PD-L1 inhibitor ,chemotherapy/targeting | Beijing Friendship Hospital | Advanced Solid Tumor | 10/22 | 10/22 | | |
NCT04669496: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors |
|
|
| Recruiting | 2/3 | 178 | RoW | Neoadjuvant treatment | Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital | Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy | 12/22 | 12/24 | | |
| Active, not recruiting | 2/3 | 402 | RoW | TORIPALIMAB INJECTION(JS001 ) | Shanghai Junshi Bioscience Co., Ltd. | Hepatocellular Carcinoma | 04/23 | 08/23 | | |
NCT05125055: Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC |
|
|
| Recruiting | 2/3 | 80 | RoW | Toripalimab (anti-programmed death-1 inhibitor), Albumin paclitaxel, Cisplatin, Docetaxel, 5-Fluorouracil | Shanghai Jiao Tong University School of Medicine | Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Chemotherapy | 09/24 | 12/26 | | |
NCT04890522: An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC |
|
|
| Not yet recruiting | 2/3 | 622 | RoW | Triprilimab(JS001), Cisplatin, 5-Fluorouracil, Gemcitabine | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd. | Nasopharyngeal Carcinoma, Metastasis, Chemotherapy, Immunotherapy, Survival | 12/23 | 12/28 | | |
NCT05817201: Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy |
|
|
| Recruiting | 2/3 | 60 | RoW | Toripalimab, JS001, TAB001, Tegafur, S-1, IMRT, Irradiation, intensity modulation radiation therapy | Taizhou Hospital | Esophageal Cancer, Radiation Therapy, Immunotherapy, Chemotherapy | 12/23 | 12/24 | | |
NCT05980481: A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer |
|
|
| Recruiting | 2/3 | 130 | RoW | RC48-ADC, Disitamab Vedotin, Trastuzumab Injection, Trastuzumab, Toripalimab, JS001, Oxaliplatin injection, Oxaliplatin, Capecitabine, Capecitabine Tablets | RemeGen Co., Ltd. | Gastric Cancer | 07/24 | 07/25 | | |
ChiCTR2300067514: The evaluation of safety and efficacy of GC 'chemo holiday' combined with lenvatinib and toripalimab for unresectable biliary tract cancers |
|
|
| Not yet recruiting | 2/3 | 30 | | (1) GC chemo holiday (2) Lenvatinib (3) Triprilizumab | Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, This work was supported by National Natural Science Foundation of China (81800540, 81827804, and 81802330). | Biliary tract cancers | | | | |
NCT04446663: Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2a | 50 | NA | Toripalimab, JS001, Albumin-bound Paclitaxel, Cisplatin, DDP, intensity-modulated radiotherapy, IMRT | First People's Hospital of Foshan | Nasopharyngeal Neoplasms | 12/23 | 12/24 | | |
NCT05342506: Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies |
|
|
| Not yet recruiting | 2a | 30 | NA | Toripalimab + ScTIL | Peking Union Medical College Hospital, Chineo Medicine (Beijing) Co., Ltd. | Cervical Cancer, Ovarian Cancer, Malignant Trophoblastic Tumor | 02/24 | 05/24 | | |
RC48-C024, CTR20231476: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab alone or in combination with toripalimab or sequential chemotherapy in patients with HR-negative, HER2-low breast cancer |
|
|
| Ongoing | 2 | | China | Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, carboplatin - Generic mfg., epirubicin - Generic mfg., cyclophosphamide - Generic mfg. | Remegen Biopharmaceutical (Yantai) Co., Ltd | HR-negative, HER2-low breast cancer | | | | |
RC48-C026, CTR20232220: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab versus pertuzumab with or without toripalimab in the neoadjuvant treatment of patients with HER2-positive breast cancer |
|
|
| Ongoing | 2 | 80 | China | Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, Perjeta (pertuzumab) - Roche | Remegen Biopharmaceutical (Yantai) Co., Ltd | HER2-positive breast cancer | | | | |
RC48-C022, CTR20233553: A phase II clinical study to evaluate the efficacy and safety of injectable vedicitumab plus toripalimab with or without chemotherapy (capecitabine + oxaliplatin) versus chemotherapy for the perioperative treatment of resectable locally advanced gastric/g |
|
|
| Recruiting | 2 | 90 | China | Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, capecitabine - Generic mfg., oxaliplatin - Generic mfg. | Remegen Biopharmaceutical (Yantai) Co., Ltd | HER2-expressing resectable locally advanced gastric/gastroesophageal junction adenocarcinoma | | | | |
ChiCTR2100049563: A single-arm, phase II study to toripalimab combined with pazopanib in treatment of patients with simple lung metastasis clear cell renal cell carcinoma before operation |
|
|
| Not yet recruiting | 2 | 40 | China | Toripalimab combined with pazopanib | Fudan University Shanghai Cancer Center ; Fudan University Shanghai Cancer Center, No | Clear Cell Renal Cell Carcinoma | | | | |
zs-ICC-2019, NCT03951597: Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 30 | RoW | combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001) | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 01/20 | 11/21 | | |
NCT04177797: Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 2 | 20 | RoW | Toripalimab | Sichuan Cancer Hospital and Research Institute | Esophageal Squamous Cell Carcinoma | 06/20 | 12/23 | | |
NCT04605796: A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 2 | 54 | RoW | Toripalimab combined with Bevacizumab | Shanghai Junshi Bioscience Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/20 | 12/22 | | |
| Active, not recruiting | 2 | 25 | RoW | Tolipalimab, JS001, Reirradiation | Sun Yat-sen University | Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm | 02/21 | 02/23 | | |
NASCR, NCT03623776: Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. |
|
|
| Active, not recruiting | 2 | 80 | RoW | JS001, Toripalimab, Pemetrexed, Pemetrexed Disodium, Carboplatin, CBP, Thoracic Surgery | Sun Yat-sen University | Efficacy and Safety | 03/21 | 03/24 | | |
NCT04170179: Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis |
|
|
| Recruiting | 2 | 25 | RoW | Systemic chemotherapy, Lenvatinib, Toripalimab | Sun Yat-sen University | Hepatocellular Carcinoma | 04/21 | 04/21 | | |
ChiCTR1900023710: Toripalimab combined with capecitabine for locally persistent nasopharyngeal carcinoma after radical chemoradiotherapy: a prospective, single-arm, phase II trial |
|
|
| Not yet recruiting | 2 | 23 | China | Toripalimab combined with capecitabine | Department of Nasopharyngeal Carcinoma, Cancer Center, Sun Yat-sen University ; Sun Yat-sen University Cancer Center, Junshi Bioscieces biopharmaceutical company presents six courses of Toripalimab for each patient. | Nasopharyngeal Carcinoma | | | | |
ChiCTR2000033668: TACE and Lenvatinib Plus PD-1 Antibody Versus TACE Plus Lenvtinib for Advanced HCC: a Single-Centre Randomised Controlled Trial |
|
|
| Not yet recruiting | 2 | 80 | China | TACE+Lenvatinib plus toripalimab, an inhibitor of PD1 ;TACE+Lenvatinib | Eastern Hepatobiliary Surgery Hospital ; Eastern Hepatobiliary Surgery Hospital, Shanghai Junshi Biopharmaceutical Technology Co., Ltd. | Advanced unresectable HCC | | | | |
NCT04506281: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors |
|
|
| Recruiting | 2 | 128 | RoW | neoadjuvant treatment | Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Minhang Hospital, Fudan University, Shanghai Jinshan Hospital, Shenzhen University General Hospital | Cholangiocarcinoma, Intrahepatic | 08/21 | 08/23 | | |
BEVTOR, NCT04527068: QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | Bevacizumab, QL1101, Tripleitriumab, JS001 | Second Affiliated Hospital, School of Medicine, Zhejiang University, Qilu Pharmaceutical Co., Ltd., Shanghai Junshi Bioscience Co., Ltd. | Refractory Metastatic Colorectal Cancer, pMMR, MSS | 09/21 | 02/22 | | |
zs-ICC-2020, NCT04361331: Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 60 | RoW | Lenvatinib combined with gemox, gemox chemotherapy, Toripalimab combined with lenvatinib | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 09/21 | 12/21 | | |
ChiCTR2000031730: Open-label, single-center phase II clinical trial of low-dose dicitabine combined with triplezumab for the treatment of recurrent refractory follicular lymphoma |
|
|
| Recruiting | 2 | 46 | China | low-dose dicitabine combined with triplezumab | Cancer Prevention and Treatment Center, Sun Yat-Sen University ; Cancer Prevention and Treatment Center, Sun Yat-Sen University, Unfunded projects | Follicular lymphoma | | | | |
ZLJS2019, ChiCTR1900026420: A prospective, open-labelled, phase II clinical trial of neoadjuvant JS001 for resectable non-small cell lung cancer |
|
|
| Not yet recruiting | 2 | 45 | | After 2 cycles of neoadjuvant JS001 (3mg/kg Q2W, ivdrip), all participants will undergo curative resection of lung cancer. | Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, Junshi Bioscieces | Non-small cell lung cancer | | | | |
ChiCTR2000029713: Albumin paclitaxel plus platinum and toripalimab as first-line treatment for recurrent/metastatic head and neck squamous cell carcinaoma: Phase II Clinical Trial |
|
|
| Not yet recruiting | 2 | 37 | China | Albumin paclitaxel plus platinum and toripalimab | Shenzhen Hospital of cancer hospital of Chinese Academy of Medical Sciences ; Cancer Hospital of Chinese Academy of Medical Sciences, Shenzhen Center, Raise independently | Head and neck squamous cell carcinaoma | | | | |
NCT03925090: Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients |
|
|
| Active, not recruiting | 2 | 150 | RoW | Cisplatin+Toripalimab, DDP+ JS001, Cisplatin+placebo, DDP | Sun Yat-sen University | Nasopharyngeal Carcinoma | 12/21 | 10/23 | | |
NCT04301557: PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 25 | RoW | PD-1 Antibody, Toripalimab, Oxaliplatin, Capecitabine, External beam radiotherapy, Total mesorectal excision | Sun Yat-sen University | DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Locally Advanced Colorectal Cancer | 04/24 | 12/24 | | |
ChiCTR2000029277: Neoadjuvant Toripalimab in Combination With SABR in Resectable NSCLC |
|
|
| Recruiting | 2 | 30 | China | Toripalimab +SABR | Jinling Hospital ; Jinling Hospital, No | Non small cell lung cancer | | | | |
NCT04437212: Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer |
|
|
| Recruiting | 2 | 20 | RoW | Toripalimab, JS-001 | RenJi Hospital | Advanced Esophageal Squamous Cell Cancer | 12/21 | 12/23 | | |
NCT04961788: Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Gemox combimed PD1 antibody | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 12/21 | 12/22 | | |
NCT04211012: A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma |
|
|
| Not yet recruiting | 2 | 30 | RoW | Toripalimab plus Nab-Paclitaxel +/- cisplatin | Jun Guo | Urothelial Carcinoma | 01/22 | 01/23 | | |
| Not yet recruiting | 2 | 15 | NA | Toripalimab, carboplatin, pemetrexed | Shanghai Pulmonary Hospital, Shanghai, China | Malignant Pleural Mesothelioma | 01/22 | 05/25 | | |
| Not yet recruiting | 2 | 15 | NA | Toripalimab, carboplatin, paclitaxel | Shanghai Pulmonary Hospital, Shanghai, China | Tracheal Squamous Cell Carcinoma | 01/22 | 05/25 | | |
ZLK-XXY-1, NCT04202484: Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 20 | NA | Toripalimab combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules | RenJi Hospital | Gastric Cancer | 02/22 | 02/23 | | |
NCT04296747: Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer |
|
|
| Not yet recruiting | 2 | 100 | NA | induction chemotherapy, surgery, chemoradiotherapy | Peking Union Medical College Hospital | Hypopharyngeal Squamous Cell Carcinoma | 03/22 | 03/23 | | |
GLYY-EC-NAD-01, NCT04644250: Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 32 | RoW | Toripalimab, JS-001, Paclitaxel liposome/Carboplatin, PCb, Intensity-modulated radiotherapy, IMRT | Wei Ren | Esophageal Squamous Cell Carcinoma | 03/22 | 03/24 | | |
NCT04725448: Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma |
|
|
| Recruiting | 2 | 27 | RoW | Toripalimab, JS001, Toripalimab Injection, TuoYI, Teruipuli Dankang, Bevacizumab, Bevacizumab Injection, Avastin, Bei Fa Zhu Dankang Zhusheye, Nab-paclitaxel, ABRAXANE, paclitaxel protein-bound particles for injectable suspension, Carboplatin, Carboplatin injection | Sichuan Cancer Hospital and Research Institute | Pulmonary Sarcomatoid Carcinoma, Non-small Cell Lung Cancer, Lung Diseases, Thoracic Neoplasms | 03/22 | 11/23 | | |
NCT04354662: Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer |
|
|
| Recruiting | 2 | 35 | RoW | Toripalimab, JS001, Docetaxel, Fluorouracil, Leucovorin, Oxaliplatin | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 03/22 | 06/24 | | |
NCT04316351: Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance |
|
|
| Recruiting | 2 | 60 | RoW | Toripalimab + Pemetrexed + Anlotinib, JS001 | Guangzhou Institute of Respiratory Disease, Shanghai Junshi Bioscience Co., Ltd. | IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy | 04/22 | 04/22 | | |
| Recruiting | 2 | 38 | RoW | niraparib combined with brivanib, Treatment group1, niraparib combined with toripalimab, Treatment group2 | Chongqing University Cancer Hospital | Cervical Cancer | 04/22 | 07/22 | | |